Utility of Intraoperative Parathyroid Hormone Monitoring in Patients with Multiple Endocrine Neoplasia Type 1-Associated Primary Hyperparathyroidism Undergoing Initial Parathyroidectomy

被引:15
|
作者
Nilubol, Naris [1 ]
Weisbrod, Allison B. [1 ]
Weinstein, Lee S. [2 ]
Simonds, William F. [2 ]
Jensen, Robert T. [3 ]
Phan, Giao Q. [4 ]
Hughes, Marybeth S. [4 ]
Libutti, Steven K. [5 ]
Marx, Stephen [2 ]
Kebebew, Electron [1 ]
机构
[1] NCI, Endocrine Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[2] NIDDK, Metab Dis Branch, NIH, Bethesda, MD USA
[3] NIDDK, Digest Dis Branch, NIH, Bethesda, MD USA
[4] NCI, Surg Branch, Ctr Canc Res, NIH, Bethesda, MD 20816 USA
[5] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Surg, Bronx, NY 10467 USA
基金
美国国家卫生研究院;
关键词
MINIMALLY INVASIVE PARATHYROIDECTOMY; ASSAY; DISEASE; CRITERIA; SURGERY; ADENOMA;
D O I
10.1007/s00268-013-2054-1
中图分类号
R61 [外科手术学];
学科分类号
摘要
Intraoperative parathyroid hormone monitoring (IOPTH) is a widely used adjunct for primary hyperparathyroidism (pHPT). However, the benefit of IOPTH in familial pHPT, such as in multiple endocrine neoplasia type I (MEN1), remains unclear. We performed a retrospective analysis of 52 patients with MEN1-associated pHPT undergoing initial parathyroidectomy with IOPTH monitoring at our institution. Parathyroid hormone (PTH) levels were measured before skin incision and 10 min after resection of the last parathyroid gland. Variables analyzed included percent drop of PTH from baseline and the final PTH level compared to the normal reference range (RR). A total of 52 patients underwent initial subtotal parathyroidectomy with IOPTH. An IOPTH decrease cutoff of a parts per thousand yen75 % from baseline had the highest biochemical cure rate (87 %). In the remaining 13 % who met this cutoff, all had persistent pHPT, with a parts per thousand yen90 % drop of PTH from baseline. The remaining patients, who did not meet the a parts per thousand yen75 % cutoff, were cured. Follow-up was available for three of four patients with final IOPTH levels above the RR: one had persistent pHPT, two had hypoparathyroidism (50 %). When a postresection PTH level was within the RR, 88 % of patients were cured. While considered cured from pHPT, 7 % of patients in this group developed permanent hypoparathyroidism. When the final PTH level dropped below the RR, 28 % developed permanent hypoparathyroidism. A cutoff in IOPTH decrease of a parts per thousand yen75 % from baseline has the highest biochemically cure rate in patients with pHPT associated with MEN1. However, a 75 % cutoff in IOPTH decrease does not exclude persistent pHPT. The absolute IOPTH value does not accurately predict postoperative hypoparathyroidism.
引用
收藏
页码:1966 / 1972
页数:7
相关论文
共 39 条
  • [31] Applicability of a shortened interpretation model for intraoperative parathyroid hormone monitoring in patients with primary hyperparathyroidism in an endemic goiter region
    Philipp Riss
    Angelika Geroldinger
    Andreas Selberherr
    Lindsay Brammen
    Julian Heidtmann
    Christian Scheuba
    European Surgery, 2018, 50 : 228 - 231
  • [32] Single Centre Experience in Patients with Primary Hyperparathyroidism: Sporadic, Lithium-associated and in Multiple Endocrine Neoplasia
    Dillenberger, Sabine
    Bartsch, Detlef K.
    Maurer, Elisabeth
    Kann, Peter Herbert
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2020, 128 (10) : 693 - 698
  • [33] A randomized, prospective trial of operative treatments for hyperparathyroidism in patients with multiple endocrine neoplasia type 1
    Lairmore, Terry C.
    Govednik, Cara M.
    Quinn, Courtney E.
    Sigmond, Benjamin R.
    Lee, Cortney Y.
    Jupiter, Daniel C.
    SURGERY, 2014, 156 (06) : 1326 - 1335
  • [34] Diagnostic Utility of Menin Immunohistochemistry in Patients With Multiple Endocrine Neoplasia Type 1 Syndrome
    Verschuur, Anna Vera D.
    Kok, Aranxa S. M.
    Morsink, Folkert H. M.
    de Leng, Wendy W. J.
    van den Broek, Medard F. M.
    Koudijs, Marco J.
    Offerhaus, Johan A.
    Valk, Gerlof D.
    Vriens, Menno R.
    van Nesselrooij, Bernadette P. M.
    Hackeng, Wenzel M.
    Brosens, Lodewijk A. A.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2023, 47 (07) : 785 - 791
  • [35] Primary hyperparathyroidism in patients with multiple endocrine neoplasia type 1: Impact of genotype and surgical approach on long-term postoperative outcomes
    Shariq, Omair A.
    Abrantes, Vitor B.
    Lu, Lauren Y.
    Tebben, Peter J.
    Foster, Trenton M.
    Dy, Benzon M.
    Lyden, Melanie L.
    Young, William F.
    McKenzie, Travis J.
    SURGERY, 2024, 175 (01) : 8 - 16
  • [36] High prevalence of chronic kidney disease in patients with multiple endocrine neoplasia type 1 and improved kidney function after parathyroidectomy
    Green, Patience
    Zagzag, Jonathan
    Patel, Dhaval
    Weinstein, Lee S.
    Simonds, William F.
    Blau, Jenny
    Marx, Stephen
    Kebebew, Electron
    Perrier, Nancy
    Nilubol, Naris
    SURGERY, 2019, 165 (01) : 124 - 128
  • [37] An analysis of genotype-phenotype correlations and survival outcomes in patients with primary hyperparathyroidism caused by multiple endocrine neoplasia type 1: the experience at a single institution
    Horiuchi, Kiyomi
    Okamoto, Takahiro
    Iihara, Masatoshi
    Tsukada, Toshihiko
    SURGERY TODAY, 2013, 43 (08) : 894 - 899
  • [38] Is intraoperative parathyroid hormone monitoring necessary with ipsilateral parathyroid gland visualization during anticipated unilateral exploration for primary hyperparathyroidism: A two-institution analysis of more than 2,000 patients
    Rajaei, Mohammad H.
    Oltmann, Sarah C.
    Adkisson, Cameron D.
    Elfenbein, Dawn M.
    Chen, Herbert
    Carty, Sally E.
    McCoy, Kelly L.
    SURGERY, 2014, 156 (04) : 760 - 768
  • [39] Elevated levels of circulating microbial-associated uremic toxins are associated with metastatic duodenopancreatic neuroendocrine tumors in patients with Multiple Endocrine Neoplasia Type 1
    Ballaro, Riccardo
    Wasylishen, Amanda R.
    Pieterman, Carolina R. C.
    Olsen, Courtney
    Irajizad, Ehsan
    Wu, Ranran
    Katayama, Hiroyuki
    Liu, Huiling
    Cai, Yining
    Leon-Letelier, Ricardo A.
    Dennison, Jennifer B.
    Waguespack, Steven
    Doe, Kim-Anh
    Agarwal, Sunita K.
    Walter, Mary
    Welch, James
    Weinstein, Lee
    Blau, Jenny E.
    Jha, Smita
    Nilubol, Naris
    Vriens, Menno R.
    van Leeuwaardej, Rachel S.
    van Treijenj, Mark J. C.
    Valk, Gerlof D.
    Perrierd, Nancy D.
    Hanasha, Samir M.
    Fahrmann, Johannes F.
    CANCER LETTERS, 2025, 614